Bicocca Open Archive

Logo unimib boa
RUPERTO, Nicolino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 186
NA - Nord America 164
EU - Europa 60
Totale 410
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 160
ID - Indonesia 89
SG - Singapore 69
DE - Germania 15
CN - Cina 13
IN - India 10
IT - Italia 10
FI - Finlandia 9
FR - Francia 9
AT - Austria 7
CA - Canada 4
HK - Hong Kong 4
PL - Polonia 3
GB - Regno Unito 2
SE - Svezia 2
BE - Belgio 1
NL - Olanda 1
PH - Filippine 1
UA - Ucraina 1
Totale 410
Salva come PNG Salva come JPEG
Città #
Jakarta 89
Singapore 65
Helsinki 8
Hyderabad 8
Xi'an 7
Guangzhou 6
Hong Kong 4
Nuremberg 3
Ashburn 2
Catanzaro 2
Coimbatore 2
Lodz 2
London 2
New York 2
North Vancouver 2
Paris 2
Seriate 2
Turin 2
Corciano 1
Florence 1
Frankfurt am Main 1
Gdansk 1
Ghent 1
Gothenburg 1
Hisings Backa 1
Manila 1
Milan 1
Vienna 1
Totale 220
Salva come PNG Salva come JPEG
Nome #
Correction to: S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis (Arthritis Research & Therapy, (2024), 26, 1, (125), 10.1186/s13075-024-03347-0) 17
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review 13
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison 12
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 11
Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use 11
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry 11
Breaking down the fences among registries on autoinflammatory diseases: the E-Merge project 11
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial 10
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee 10
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 10
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 10
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 10
Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials 10
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 9
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis 9
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 9
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group 9
Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry 9
Development and External Validation of a Model Predicting New-Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis 9
Response to: 'Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?' by Fayand et al 9
Juvenile idiopathic arthritis 9
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 9
Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): An international survey 9
Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis 9
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 8
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 8
Tofacitinib for juvenile idiopathic arthritis – Authors' reply 8
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study 8
Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry 8
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: A randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial 8
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 8
Development and testing of reduced versions of the MMT-8 in juvenile dermatomyositis 8
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 8
A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis 8
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate 8
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial 8
Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way 8
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: Post hoc radiographic analysis from two randomized controlled trials 8
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 8
Some clarifications on the new classification criteria for recurrent fevers 7
Emerging therapies for juvenile arthritis: agents in early clinical trials 7
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis 7
Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study 7
Performance of the 2016 ACR-EULAR myositis response criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles 7
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 7
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 7
Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis 7
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 7
Reply 7
Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings 7
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis 7
Classification criteria for autoinflammatory recurrent fevers 7
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 7
Outcome Scores in Pediatric Rheumatology 7
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 7
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 7
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial 7
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis 6
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 6
Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey 6
Corrigendum to The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort (Seminars in Arthritis and Rheumatism (2022) 52, (S0049017222000087), (10.1016/j.semarthrit.2022.151957)): <[ Seminars in Arthritis and Rheumatism Volume 52, 151957]> 6
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis 6
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 6
Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3) 6
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 6
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 6
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 6
Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: Multicenter international study 6
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 6
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 6
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 5
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 5
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 5
Biological classification of childhood arthritis: roadmap to a molecular nomenclature 5
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 5
Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry 5
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 5
The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort 5
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 5
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Abatacept 5
"To Randomize, or Not to Randomize, That is the Question" 5
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients 5
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 5
Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis 5
Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis 5
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 5
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA 5
The European network for care of children with paediatric rheumatic diseases: care across borders 5
INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry 5
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 5
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 5
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 5
Publisher Correction: Biological classification of childhood arthritis: roadmap to a molecular nomenclature (Nature Reviews Rheumatology, (2021), 17, 5, (257-269), 10.1038/s41584-021-00590-6) 5
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 4
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 4
Treatment of juvenile idiopathic arthritis: what's new? 4
American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus 4
An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome 4
Totale 704
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.300
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.300
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025704 0 0 0 0 605 99 0 0 0 0 0 0
Totale 704